ArticleFrontiers in endocrinology2026
Association of serum 25-hydroxyvitamin D levels with indicators of target organ damage in patients with diabetes: a cross-sectional study.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To assess serum 25-hydroxyvitamin D [25(OH)D] in relation to indicators of target organ damage in patients with diabetes. Methods: This analysis included 372 adults with diabetes who underwent serum 25(OH)D testing in the Department of Endocrinology at Jen Ching Memorial Hospital from January 1 to December 31, 2025. Data on demographic characteristics, medical history, laboratory parameters, carotid ultrasonography, and electrophysiological examinations were collected. We performed multivariable regression models to examine the associations of serum 25(OH)D levels with peripheral nerve dysfunction, carotid plaque, urinary microalbumin (mALB), cerebral infarction, and coronary heart disease (CHD). Restricted cubic spline (RCS), threshold effect, and sensitivity analyses were further employed. Results: Serum 25(OH)D was inversely associated with peripheral nerve damage and carotid plaque. After adjustment for all prespecified covariates, the corresponding odds ratios were 0.941 (95% Conclusions: Among patients with diabetes, lower serum 25(OH)D levels were associated with peripheral nerve damage, carotid plaque, and higher mALB levels. These findings support an association between serum 25(OH)D and indicators of diabetes-related target organ damage, but prospective studies are needed to clarify the temporal and clinical significance of these associations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.